Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveRingCentral Reports Third-Quarter Revenue of $676 Million

Live News EQUITY FLASH M impact Oct 22, 2026, 08:03 PM UTC

RingCentral Reports Third-Quarter Revenue of $676 Million

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

RNG

Related stories

First Quantum Plans Argentina Tax-Break Application for Copper Project Argentina’s foreign minister said First Quantum Minerals expects to apply for the country’s large investment tax-break scheme before year-end. The Taca Taca copper project investme M impact | EQUITY | Oct 23, 2026, 04:03 PM UTC GrafTech Reports Q3 2026 Revenue of $140.16M, Net Loss of $46.77M GrafTech reported diluted loss per share of $1.76, compared with $1.10 a year earlier. Revenue was $144 million and net loss was $28.48 million in the prior-year quarter. M impact | EQUITY | Oct 23, 2026, 04:01 PM UTC Biosynex Wins $5.7M BARDA-Supported Award for Biothreat Test Subsidiary Chembio received a BARDA-supported award to advance its DPP Biothreat Panel over 20 months, aiming for FDA clearance of a rapid multiplex test for three pathogens and in M impact | EQUITY | Oct 23, 2026, 04:01 PM UTC US session market picture: S&P 500 -0.23%, Nasdaq 100 +0.39%; EUR/USD -0.18%, WTI +3.6%, WBD leads volume US session market picture. US index futures: S and P futures is down 0.23 percent, Nasdaq futures is up 0.39 percent, Dow futures is down 1.03 percent and Russell futures is down 0 M impact | EQUITY | Oct 23, 2026, 04:00 PM UTC Genmab Phase 3 Trial of Rina-S Meets PFS and OS Endpoints Genmab said the RAINFOL-02 trial met its progression-free and overall survival endpoints in platinum-resistant ovarian cancer. PFS hazard ratio was 0.29 in the ITT population and O M impact | EQUITY | Oct 23, 2026, 03:56 PM UTC Genmab Says Rina-S Shows Significant PFS and Overall Survival Improvement Genmab announced positive topline Phase 3 results for rinatabart sesutecan in patients with platinum-resistant ovarian cancer. M impact | EQUITY | Oct 23, 2026, 03:56 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.